Could a wakefulness drug tame MS fatigue?
NCT ID NCT06170970
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether solriamfetol (Sunosi), a drug used for sleepiness, can reduce fatigue in people with multiple sclerosis who also have excessive daytime sleepiness. About 46 participants will receive either the drug or a placebo for four weeks, then switch after a washout period. The study uses a smartphone app to track fatigue through typing patterns, aiming for more precise measurements.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Solriamfetol (Sunosi)
What this could lead to
If it works, this could offer a new treatment option for fatigue in people with multiple sclerosis who also have excessive daytime sleepiness.
What could go wrong
This is a small, early-phase trial (46 people) and may not show clear benefit. Fatigue is complex, and results may not apply to everyone with MS.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••